NuCana is trading at $1.05, up 5.93%, alongside a strong biotech-sector backdrop that may help explain its October 21 pre-market move; no company-specific catalyst was identified. - The XBI ETF was reported up 3.64% pre-market. - NuCana’s latest identified company news was its September 30 European patent announcement. Shares had also gained 2.91% at the October 20 close.